Anne-Lise Børresen-Dale

  • Professor emerita; PhD, MD (h.c.)
  • +47 22 78 13 73

Born 030746, Molde, Norway

Addresses:

1. Department of Genetics, Institute for Cancer Research, Oslo University Hospital The Norwegian Radiumhospital.

2. Institute for Clinical Medicine, Faculty of Medicine University of Oslo, Norway.

Phone: +4722781373, Fax: +4722781395 Cell phone: +4792854455

Email: a.l.borresen-dale@medisin.uio.no

Anne-Lise Børresen-Dale is Professor Emerita at University of Oslo and previous head of Department of Cancer Genetics, Oslo University Hospital Radiumhospitalet. She is among the leading geneticists in research on molecular biology of breast cancer, and her group was among the pioneers in expression profiling of breast carcinomas in collabora­tion with groups at Stanford, demonstrating that breast cancer can be divided into distinct sub-groups with differences in molecular profiles and in overall and relapse-free survival. Her achievements are seminal for understanding breast cancer evolution, and have had an enormous impact on our view of the complexity of breast cancer. She is author of more than 500 published scientific papers, books chapters and invited reviews.

Børresen-Dale was director of the K.G. Jebsen Center for Breast Cancer Research with a major funding from the K.G. Jebsen Foundation in the period 2011-2016. (http://stiftkgj.no/hva-vi-gjor/k-g-jebsen-medisinske-sentre/k-g-jebsen-senter-for-brystkreftforskning/)

Børresen-Dale has received several prizes and awards, some of the most prestigious being the Swiss Bridge Award for Outstanding Cancer Research in 2004, the Möbius prize for outstanding Research from the Research Council of Norway in 2008, The Mildred Scheel Lecturership in 2015, the Fritjof Nansen medal and award for Outstanding Research from the Academy of Science and Letters, Norway in 2015, the AACR Distinguished Lectureship in Breast Cancer Research in 2015 and the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship and award in 2017. She was appointed to Commander of the Royal Norwegian St. Olavs Order by the King of Norway in 2017. Børresen-Dale has been Member of the Board of Directors of both AACR and ECCO, is past president of EACR, and is Elected Member of The Royal Academy of Science, Norway, The Norwegian Academy of Science and Letters and the European Academy of Cancer Sciences.

Børresen-Dale's research has been focusing on Exploring the Systems Biology of Breast Cancer using high dimensional data in integrated approaches aiming at identification of genotypes and gene expression profiles contributing to elevated cancer risk, radiation sensitivity, tumor aggressiveness and therapy resistance. The goal has been to follow the linear time course of predisposition, initiation, early stages and advanced disease and to dissect the molecular mechanisms triggered at each stage and to follow the multidimensional interactions at various levels in a systems biology approach to be able to better do risk estimation, prognostication and prediction.

Ongoing external activities:

Academic Degrees.

1970 M.Sc. Biochemistry, Technical University of Norway, Trondheim, Norway.

1978 Doctor of Science in Medical Biochemical Genetics, University of Oslo, Norway.

1987 Judged qualified as a professor in gene technology, University of Oslo, Norway.

1992 Professor in Molecular Tumor biology, Univ. of Oslo, Norway (still holding)

Main Positions held

1970-72 Research assistant, Institute of Medical Genetics, University of Oslo.

1972-78 Research Fellow, Institute of Medical Genetics, University of Oslo.

1978-82 Senior Research Fellow, Institute of Medical Genetics, University of Oslo

1982-86 Senior Biochemist, Head, section for prenatal diagnosis, Department of Medical Genetics, UiO

1987-99 Senior Scientist, Dept. of Genetics, Inst. for Cancer Research, DNR, Norway

1999-present Head of Department, Dept. Genetics, Inst. for Cancer Research, OUS/DNR, Norway

Honors and awards

1989 Prof.Olav Torgersens Prize and Memorial Lecture: Gene tech. in the fight against cancer.

1989 Honorary lecturer at the 175th anniversary of the Medical Faculty, Univ.Oslo.

1994 King Olav V's Cancer Research Prize

1998 Member of The Royal Academy of Science, Norway

2001 Honorary member of The Norwegian Biochemical Society

2002 University of Oslo's Research Prize for Outstanding Research

2002 SalusAnsvar Medical prize for Outstanding Research in Tumor biology

2002 The Employer of the year at The Norwegian Raduimhospital

2004 Member of The Norwegian Academy of Science and Letters

2004 Swiss Bridge Award for outstanding Cancer Research

2008 Doctor medicinae honoris causa, University of Copenhagen

2008 The Möbius prize for outstanding Research from The Research Council of Norway

2009 ESTRO Honorary member award

2009 International Journal of Cancer/ Meyenburg-Stiftung Joint Lectureship distinguished speaker

2009 Elected member of the European Academy of Cancer Sciences

2009 Associate Investigator of Centre for Molecular medicine (NCMM), Nordic EMBL Partnership

2010 Honorary ambassador of the Norwegian Cancer Society

2012 Honorary member of The Hungarian Cancer Societ 

Research work abroad (3-6 months)

1972: Dep. Hum.Biol.Chem& Gen, Univ. Texas, (Barbara Bowman), protein sequencing.

1977: The Rockefeller University, New York (Thomas Kindt), protein sequencing

1985: EMBL (Hans Lerach), recombinant DNA‑techniques

1986: Recombinant DNA Tech. Lab, Helsinki, Finland (Leena Peltonen,)

1990: Harvard Med. Sch., Mass. (David Yandell), PCR/SSCP on Rb,

1992: MIT, Cent. Envir. Health Sci. MA (William Thilly), mutation assay systems

1992: MGH Cancer Cent and Harvard Med. Sch, Boston, MA (Stephen Friend)

2002: Visiting Prof, Dept of Genetics, Stanford Univ.CA (David Botstein), Microarray analyses.

Teaching responsibilities

Supervised: 40 PhD stud (22 as main supervisor, 5 ongoing, 3 as main), 18 MSc stud. (10 as main superv)

PBL Medical Students since 96.

Selective Administrative Experience on national and international Boards

1986-91: Secretary General, The Norwegian Biochemical Society.

1989-1993: PI of a Nordic technology development project financed by Nordisk Industrifond

1995-00: Chair of expert committee on Biotech. and Genetics. Norwegian Board of Health.

1995-00: Chairman of the program committee, MedKap, NFR

1999-02: Member of the Scientific Council, International .Agency for Res. of Cancer, IARC, Lyon

2002-03: Vice-Chairman of the Scientific Council, IACR, Lyon

2001-04: Board member of the National Committee for Functional Genomics, FUGE

2003-06: Member of The Board of Directors, American Ass. for Cancer Res. (AACR)

1996-06 Member of The Scientific Board "Forskningutvalget" DNR/RR-HF.

2004-08 One of the PI's in the EU Integrated project on "Mutant TP53 and Cancer"

2000 Member of the Scientific Committees for the 2nd ESF conference, and ECCO 13

2006- 08 President Elect, European Association for Cancer Research, EACR

2007- Scientific Advisory Board, CREATE HEALTH Consortium Lund Sweden

2008-10 President EACR

2008-12 Board of Directors and Executive committee as Treasure, ECCO (European CanCer Organization)

2008-10 Member of the Nomination Committee, AACR

2008- External Advisory Board (EAB) of the SPORE in Breast Cancer at Univ. of North Carolina

2010-13 Scientific Advisory Board member, DKZF, Heidelberg, Germany'

2011-13 Council of Scientific Advisors, AACR (American Association for Cancer Research)

2011 Scientific co-chair, ECCO16 Conference, Stockholm

2011- Senior Associated Editor, Molecular Oncology

2011-16 Director of the K.G.Jebsen Centre for Breast Cancer Research

2011-14 Chair of Scientific Advisory Board for TRANSCAN ERA-net

2012 Chair and organizer of International Symposium on Personalized Cancer Care

2013- Scientific Board of the Pezcoller Foundation

2013-16 Scientific Advisory Board, German Consortium for Translational Cancer Research (DKTK)

2013 Basic Science track chair, ECCO17 Conference, Amsterdam

2013-18 External Advisory Group, ReQuiTe: Radiotherapy for Quality of life through reduced Toxicity

2014-15 Breast Cancer track chair, ECCO18 Conference, Vienna

Publications:

Author of 438 published/in press scientific papers, 40 chapters in books and invited reviews, 33 articles in Nordic journals and books

Main funding

1) Annually from the Cancer Society of Norway, on Exploring the Systems Biology of Breast Cancer.

Pt: One postdoc (50%, ending march 2015) one postdoc 100% ( to start August 2014), 2 technicians and laboratory expenses

2) 2011-2015: Funding for a K.G Jebsen Center for Breast Cancer Research

3) 2013-2017: Funding from HSØ for a PhD student and a post doc in the project : Exploring the Systems Biology of Breast Cancer, focusing on noncoding RNA and its role in breast cancer progression

4) 2012-2015: NFR grant together with GM Mælansdmo, MetAction: Actionable Targets in Cancer Metastasis - from Bed to Bench to Byte to Bedside

5) EU-7FP: BASIS: Breast Cancer Somatic Genetics Study under HEALTH-2009-2.1.1-2: Large-scale functional genomics efforts to identify molecular determinants of cancer:

6) EU-7FP: "GlycoHIT: Glycomics by High-throughput Integrated Technologies: Development and validation of complementary and integrated technologies for glycomic analysis of serum in cancer glycobiomarker discovery, diagnostics and glycotherapeutic monitoring" under HEALTH 2010.1.1-3: High-throughput analysis of posttranslational modifications of proteins.

7) EU-7FP: "EUROCANPLATFORM" A European Platform for Translational Cancer Research: Network of Excellence under HEALTH 2.4.1-2 .

Selected peer-reviewed publications (from a total of 458)

Citations(>10) per May 28. 2014 marked in blue

1. Perou, CM., Sørlie, T., Eisen, MB., van de Rijn, M., Jeffrey, S. S., Pollack, JR., Rees, CA., Ross, DT., Johnsen, H., Akslen, LA., Pergamenschikov, CW., Zhu, SX., Lønning, PE., Børresen-Dale, AL., Brown, PO. and Botstein, D.: Molecular portraits of human breast tumours. Nature 406: 747-52, 2000. 7724 citations

2. Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Hastie, T., Johnsen, H., Eisen, M.B., Thorsen, T., Rijn, M. van der., Jeffrey, S., Quist, H., Rees, C. A., Brown, P.O., Botstein, D., Lønning, P.E. and Børresen-Dale, A.-L.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with potential clinical implications. PNAS 98 (19): 10869-74, 2001. 5980 citations

3. Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Perou, C. M., Lønning, P. E., Brown, P. O., Børresen-Dale, A.-L., and Botstein, D.: Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS., 100 (14): 8418-8423, 2003. 3387 citations

4. Hicks, J., Krasnitz, A., et al and Børresen-Dale, A.-L., Naume, B., Schlicting, E., Norton, L., Hagerstrøm,T., Skoog,L., Auer, G,. Måner, S., Lundin, P. and Zetterberg, A.: Novel patterns of genome rearrangements and their association with survival in breast cancer. Genome Res. 16(12):1465-79, 2006. 209 citations

5. Horlings H.M., Bergamaschi A., Nordgard, S H., Kim Y H., Han W., Noh DY., Salary, K., Joosse, S. A., Reyal, F., Lingjaerde, O. C., Kristensen V.N., Børresen-Dale A-L., Pollack J.R. and van de Vijver M.J.: ESR1 gene amplification in breast cancer: a common phenomenon? Letter to editor of Nature Genetics on the publication of Frederik Holst et al. in Nature Genetics 39, 655 - 660 (2007), Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 40(7): 807-808, 2008. 85 citations

6. Stephens, P. J., McBride, D. J., et al and, Børresen-Dale, A.-L., Campbell, P. J., Futreal, P. A. and Stratton, M. R.: Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 462(7276):1005-10, 2009. 450 citations

7. Russnes, H. G., Vollan, H. K. M., Lingjærde, O. C., Krasnitz, A., Lundin, P., Naume, B., Sørlie, T., Borgen, E., Rye, I. H., Langerød, A., Chin, S-F., Teschendorff, A. E., Stephens, P. J., Månèr, S., Schlichting, E., Baumbusch, L. O., Kåresen, R., Stratton, M. P., Wigler, M., Caldas, C., Zetterberg, A., Hicks, J. and Børresen-Dale, A.-L.: Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Science Translation Medicine, 2, 38ra47 (2010) 78 citations

8. Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., Perou, C. M., Børresen-Dale, A.-L. and Kristensen, V. N.: Allele specific copy number analysis in tumors (ASCAT). 2010. PNAS 107 (39) 16910-16915 Sep.28, 2010, www.pnas.org/cgi/doi/10.1073/pnas.100984310 118 citations

9. Potapenko, I. O., Haakensen, V. D., Lüders, T., Helland, Å., Bukholm, I. R., Sørlie, T., Kristensen, V.N., Lingjærde, O. C. and Børresen-Dale, A.-L.: Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. 2009. Molecular Oncol. 4(2):98-118, 2010. 39 citations

10. Hennessy, B. T., Lu, Y., Gonzalez-Angulo, A.M., Carey , M. S., Myhre, S., Ju, Z., Davies, M. A., Liu, W., Coombes, K., Meric-Bernstam, F., Bedrosian, I., McGahren, M., Agarwal, M., Zhang, F., Overgaard, J., Alsner, J., Neve, R. M., Kuo, W.-L., Gray, J. W. , Borresen-Dale, A.-L. and Mills, G. B.: A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin.Proteom 6:129-151, 2010. 54 citations

11. Enerly, E., Steinfeld, I., Kleivi, G. K., Leivonen, S. K., Aure, M. R., Russnes, H. G., Rønneberg, J. O., Johnsen, H., Navon, R., Rødland, E., Mäkalä, R., Naume, B., Perälä, M., Kallioniemi, O., Kristensen, V. N., Yakhini, Z. and Børresen-Dale, A.-L.: miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. Plos One, 2011 Feb 22:6 (2) e16915 100 citations

12. Edgren H, Murumägi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Wolf M,Børresen-Dale, A.-L. and Kallioniemi O.: Identification of fusion genes in breast cancer by paired- end RNA-sequencing. Genome Biology, 2011 jan.19:12(1):R6. 72 citation

13. Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale, A.-L., and Lindgjærde OC.: Combining gene signatures improves prediction of breast cancer survival. PLoS One, 2011 Mar.10;6(3) e17845. 22 citation

14. Russnes HG, Navin N, Hicks J, Borresen-Dale A.-L.: Insight into the Heterogeneity of Breast Cancer through Next-Generation Sequencing. JCI, Oct 3; 121(10) 3810-8, 2011 70 citation

15. Kristensen, V.N., Vaske, C et al and Børresen-Dale, A.-L.: Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. PNAS Sep 9, 2011 42 citations

16. Curtis C., Shah S.P., Chin S.-F. et al and Børresen-Dale, Brenton J.D., Tavare´S., Caldas C. & Aparicio S.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486 (7403), 346-52, 2012. 484 citations

17. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Børresen-Dale A.-L., Levine AJ, Bargonetti J and Prives C. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell.;148(1-2):244-58, 2012. 99 citations

18. Stephens, P.J., Tarpe P et al and, Børresen- Dale,A.-L., Richardson,A.L., Campbell,P.J., P Andrew Futreal,P.A. and Stratton,M.R. The landscape of cancer genes and mutational processes in breast cancer. Nature 486 (7403), 400-4, 2012. 325 citations

19. Nik-Zainal S, van Loo P, Wedge DC et al and Børresen-Dale A.-L, Futreal PA, Stratton MR and Campbell PJ: The Life History of 21 Breast Cancers. Cell, 149 (5), 994-100, 2012. 242 citations

20. A. Margolin, E. Bilal, E. Huang, T. C. Norman, L. Ottestad, et al and The Sage DREAM Breast Cancer Challenge Consortium, V. N. Kristensen, J. Hellerstein, S. Friend, G. Stolovitzky, S.Aparicio, C. Caldas, A.L. Børresen-Dale Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer 2013 Science Translational Medicine, 17 April 2013 Vol 5 Issue 181 181re1.

21. Aure, M. R., Steinfeld, I., Baumbusch, L.O., Lilestøl, K., Lipson, D., Nyberg, S., Naume, B., Sahlberg, K. K., Kristensen, V. N., Børresen-Dale, A.-L., Lingjærde, O.C. and Yakhini, S.: Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. PlosOne, 2013(8)1e53014

22. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio S, Behjati S,. Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A.-L... Pfister SM, Campbell PJ, and Stratton MR: Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. 128 citations

23. Engebraaten, Vollan, H.K.M., and Børresen-Dale, A.L.:Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol. 2013 Aug 3. piiS0002-9440(13)00461-6. doi: 10.1016/j.ajpath.2013.05.033

24. Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors. Genome Biol, 14 (11), R126 PubMed 24257477

25. Vessela N. Kristensen, Ole Christian Lingjærde, Hege G. Russnes, Hans Kristian M. Vollan, Arnoldo Frigessi, and Anne-Lise Børresen-Dale: Principles and methods of integrative genomic analyses in cancer, Nature Cancer Reviews, VOLUME 14 | MAY 2014 | 303

Download CV in Word format

Publications 2009-2014 - download in Word format

 
Scroll to top